001     143578
005     20240229123016.0
024 7 _ |a 10.1111/nan.12560
|2 doi
024 7 _ |a pmid:31077608
|2 pmid
024 7 _ |a 0305-1846
|2 ISSN
024 7 _ |a 1365-2990
|2 ISSN
024 7 _ |a altmetric:60340966
|2 altmetric
037 _ _ |a DKFZ-2019-01158
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Hasselblatt, Martin
|b 0
245 _ _ |a Tyrosinase immunohistochemistry can be employed for the diagnosis of atypical teratoid/rhabdoid tumours of the tyrosinase subgroup (ATRT-TYR).
260 _ _ |a Oxford [u.a.]
|c 2020
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1597225956_3553
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Feb;46(2):186-189
520 _ _ |a Atypical teratoid/rhabdoid tumour (ATRT) is a malignant brain tumour mainly occurring in young children [1]. Mutations of chromatin remodelling complex member SMARCB1/INI1 or (rarely) SMARCA4/BRG1 are the sole recurrent genetic lesions [2, 3]. On an epigenetic level, however, ATRT is a heterogeneous disease comprised of three different molecular subgroups (ATRT-TYR, ATRT-SHH and ATRT-MYC). This article is protected by copyright. All rights reserved.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Thomas, Christian
|b 1
700 1 _ |a Nemes, Karolina
|b 2
700 1 _ |a Monoranu, Camelia-Maria
|b 3
700 1 _ |a Riemenschneider, Markus J
|b 4
700 1 _ |a Koch, Arend
|b 5
700 1 _ |a Sumerauer, David
|b 6
700 1 _ |a Hauser, Peter
|b 7
700 1 _ |a Paulus, Werner
|b 8
700 1 _ |a Johann, Pascal
|0 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8
|b 9
|u dkfz
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 10
|u dkfz
700 1 _ |a Frühwald, Michael C
|b 11
773 _ _ |a 10.1111/nan.12560
|g p. nan.12560
|0 PERI:(DE-600)2008293-9
|n 2
|p 186-189
|t Neuropathology & applied neurobiology
|v 46
|y 2020
|x 1365-2990
909 C O |o oai:inrepo02.dkfz.de:143578
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROPATH APPL NEURO : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROPATH APPL NEURO : 2017
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21